Cargando…

Recent advances and developments in COVID‐19 in the context of allergic diseases

BACKGROUND: Since the first reports of coronavirus disease 2019 (COVID‐19) in Wuhan, China, in December 2019, there have been 198 million confirmed cases worldwide as of August 2021. The scientific community has joined efforts to gain knowledge of the newly emerged virus named severe acute respirato...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Mei, Dong, Xiang, Sun, Yuan‐li, Sokolowska, Milena, Akdis, Mübeccel, van de Veen, Willem, Azkur, Ahmet Kursat, Azkur, Dilek, Akdis, Cezmi A., Gao, Ya‐dong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8646609/
https://www.ncbi.nlm.nih.gov/pubmed/34582102
http://dx.doi.org/10.1002/clt2.12065
_version_ 1784610501357993984
author Ding, Mei
Dong, Xiang
Sun, Yuan‐li
Sokolowska, Milena
Akdis, Mübeccel
van de Veen, Willem
Azkur, Ahmet Kursat
Azkur, Dilek
Akdis, Cezmi A.
Gao, Ya‐dong
author_facet Ding, Mei
Dong, Xiang
Sun, Yuan‐li
Sokolowska, Milena
Akdis, Mübeccel
van de Veen, Willem
Azkur, Ahmet Kursat
Azkur, Dilek
Akdis, Cezmi A.
Gao, Ya‐dong
author_sort Ding, Mei
collection PubMed
description BACKGROUND: Since the first reports of coronavirus disease 2019 (COVID‐19) in Wuhan, China, in December 2019, there have been 198 million confirmed cases worldwide as of August 2021. The scientific community has joined efforts to gain knowledge of the newly emerged virus named severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), the immunopathological mechanisms leading to COVID‐19, and its significance for patients with allergies and asthma. METHODS: Based on the current literature, recent advances and developments in COVID‐19 in the context of allergic diseases were reviewed. RESULTS AND CONCLUSIONS: In this review, we discuss the prevalence of COVID‐19 in subjects with asthma, attacks of hereditary angioedema, and other allergic diseases during COVID‐19. Underlying mechanisms suggest a protective role of allergy in COVID‐19, involving eosinophilia, SARS‐CoV‐2 receptors expression, interferon responses, and other immunological events, but further studies are needed to fully understand those associations. There has been significant progress in disease evaluation and management of COVID‐19, and allergy care should continue during the COVID‐19 pandemic. The European Academy of Allergy & Clinical Immunology (EAACI) launched a series of statements and position papers providing recommendations on the organization of the allergy clinic, handling of allergen immunotherapy, asthma, drug hypersensitivity, allergic rhinitis, and other allergic diseases. Treatment of allergies using biologics during the COVID‐19 pandemic has also been discussed. Allergic reactions to the COVID‐19 vaccines, including severe anaphylaxis, have been reported. Vaccination is a prophylactic strategy that can lead to a significant reduction in the mortality and morbidity associated with SARS‐CoV‐2 infection, and in this review, we discuss the proposed culprit components causing rare adverse reactions and recommendations to mitigate the risk of anaphylactic events during the administration of the vaccines.
format Online
Article
Text
id pubmed-8646609
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-86466092021-12-06 Recent advances and developments in COVID‐19 in the context of allergic diseases Ding, Mei Dong, Xiang Sun, Yuan‐li Sokolowska, Milena Akdis, Mübeccel van de Veen, Willem Azkur, Ahmet Kursat Azkur, Dilek Akdis, Cezmi A. Gao, Ya‐dong Clin Transl Allergy Review BACKGROUND: Since the first reports of coronavirus disease 2019 (COVID‐19) in Wuhan, China, in December 2019, there have been 198 million confirmed cases worldwide as of August 2021. The scientific community has joined efforts to gain knowledge of the newly emerged virus named severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), the immunopathological mechanisms leading to COVID‐19, and its significance for patients with allergies and asthma. METHODS: Based on the current literature, recent advances and developments in COVID‐19 in the context of allergic diseases were reviewed. RESULTS AND CONCLUSIONS: In this review, we discuss the prevalence of COVID‐19 in subjects with asthma, attacks of hereditary angioedema, and other allergic diseases during COVID‐19. Underlying mechanisms suggest a protective role of allergy in COVID‐19, involving eosinophilia, SARS‐CoV‐2 receptors expression, interferon responses, and other immunological events, but further studies are needed to fully understand those associations. There has been significant progress in disease evaluation and management of COVID‐19, and allergy care should continue during the COVID‐19 pandemic. The European Academy of Allergy & Clinical Immunology (EAACI) launched a series of statements and position papers providing recommendations on the organization of the allergy clinic, handling of allergen immunotherapy, asthma, drug hypersensitivity, allergic rhinitis, and other allergic diseases. Treatment of allergies using biologics during the COVID‐19 pandemic has also been discussed. Allergic reactions to the COVID‐19 vaccines, including severe anaphylaxis, have been reported. Vaccination is a prophylactic strategy that can lead to a significant reduction in the mortality and morbidity associated with SARS‐CoV‐2 infection, and in this review, we discuss the proposed culprit components causing rare adverse reactions and recommendations to mitigate the risk of anaphylactic events during the administration of the vaccines. John Wiley and Sons Inc. 2021-09-21 /pmc/articles/PMC8646609/ /pubmed/34582102 http://dx.doi.org/10.1002/clt2.12065 Text en © 2021 The Authors. Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Ding, Mei
Dong, Xiang
Sun, Yuan‐li
Sokolowska, Milena
Akdis, Mübeccel
van de Veen, Willem
Azkur, Ahmet Kursat
Azkur, Dilek
Akdis, Cezmi A.
Gao, Ya‐dong
Recent advances and developments in COVID‐19 in the context of allergic diseases
title Recent advances and developments in COVID‐19 in the context of allergic diseases
title_full Recent advances and developments in COVID‐19 in the context of allergic diseases
title_fullStr Recent advances and developments in COVID‐19 in the context of allergic diseases
title_full_unstemmed Recent advances and developments in COVID‐19 in the context of allergic diseases
title_short Recent advances and developments in COVID‐19 in the context of allergic diseases
title_sort recent advances and developments in covid‐19 in the context of allergic diseases
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8646609/
https://www.ncbi.nlm.nih.gov/pubmed/34582102
http://dx.doi.org/10.1002/clt2.12065
work_keys_str_mv AT dingmei recentadvancesanddevelopmentsincovid19inthecontextofallergicdiseases
AT dongxiang recentadvancesanddevelopmentsincovid19inthecontextofallergicdiseases
AT sunyuanli recentadvancesanddevelopmentsincovid19inthecontextofallergicdiseases
AT sokolowskamilena recentadvancesanddevelopmentsincovid19inthecontextofallergicdiseases
AT akdismubeccel recentadvancesanddevelopmentsincovid19inthecontextofallergicdiseases
AT vandeveenwillem recentadvancesanddevelopmentsincovid19inthecontextofallergicdiseases
AT azkurahmetkursat recentadvancesanddevelopmentsincovid19inthecontextofallergicdiseases
AT azkurdilek recentadvancesanddevelopmentsincovid19inthecontextofallergicdiseases
AT akdiscezmia recentadvancesanddevelopmentsincovid19inthecontextofallergicdiseases
AT gaoyadong recentadvancesanddevelopmentsincovid19inthecontextofallergicdiseases